Legal Notices and Usage Terms

Azedra.com (the “Website”) is owned and operated by Progenics Pharmaceuticals, Inc. (“Progenics”) from its offices in New York, NY, United States of America.

Progenics welcomes its customers, partners, suppliers, investors, employees, the scientific community, as well as the general public to this Website.

Progenics grants you the right to use this Website subject to the terms and conditions of use set forth below (this “Terms of Use Agreement”).

The information provided on this Website is for general informational and educational purposes only. This Website may provide information about medical conditions and their treatment. Progenics makes no representation that material on this Website is appropriate or available for use outside of the United States of America. Individuals that choose to access this Website from other locations do so on their own initiative and are responsible for compliance with local laws if and to the extent that local laws are applicable. Please read and review this Terms of Use Agreement carefully before accessing or using this Website. By accessing or using this Website, you acknowledge that you have read, understood and agreed to this Terms of Use Agreement. If you do not agree to this Terms of Use Agreement, you may not access or use the Website.

The information on this Website is provided “AS IS” without warranty of any kind whether express or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Progenics will use reasonable care to ensure that information is accurate at the time it is added to this Website but cannot guarantee this and does not accept any liability to update the information. In addition, Progenics does not accept any liability, howsoever arising, for the accuracy, completeness, use of or reliance on the information contained on this Website.

This Website may contain general information relating to various medical conditions and their treatment or direct or indirect references to Progenics’ products or product candidates. Such information is provided for informational purposes, should not be considered complete and is not meant to be a substitute for advice provided by qualified healthcare provider. You should consult a qualified healthcare provider if you have or suspect you have any health problems or should you have any healthcare-related questions. You should never disregard medical advice or delay in seeking it because of something you have read here.

All text, graphics, photographs, trademarks, logos, visual interfaces, artwork, computer code and all other related content contained on this Website is owned by Progenics or third parties and is protected by trade dress, copyright, patent and trademark laws, and various other intellectual property rights and unfair competition laws. Any reproduction, publication, further distribution or public exhibition of materials provided through this Website, in whole or in part, is strictly prohibited. You may not, distribute, modify, transmit, reuse, repost, or use the content of the Website for public or commercial purposes, including the text, images, audio, or video, without the express prior written consent of Progenics.

This Website may contain links to web sites owned or operated by third parties. The linked sites are not under the control of Progenics, which is not responsible for the content available on any linked sites. Such links do not imply endorsement of material on any linked sites and Progenics disclaims all liability with regard to your access to such linked sites. Progenics provides links to other web sites as a convenience to users, and access to such linked sites is at your own risk.

Nothing on this Website constitutes an invitation or offer to invest or deal in the securities of Progenics or an invitation by Progenics to enter into a contract with a user of this Website.

Statements in the documents or information appearing anywhere in this Website or linked to from this Website regarding Progenics’ business which are not historical facts, are “forward-looking statements” that involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialization, the impact of competitive products, patents and other risks and uncertainties, detailed from time to time in periodic reports including Progenics’ most recent Annual Report on Form 10-K and Progenics’ other filings with the Securities and Exchange Commission (SEC) available at www.sec.gov.

Failure to abide by this Terms of Use Agreement is a material breach of this Terms of Use Agreement for which Progenics may pursue all rights and remedies it has pursuant to this Terms of Use Agreement, and any other rights and remedies it may have at law or in equity. Specifically, you agree that Progenics may, in its sole discretion and without prior notice, terminate your access to this Website for violations of this Terms of Use Agreement or other agreements or guidelines which may be associated with your use of this Website.

You agree to defend, indemnify, and hold Progenics, its officers, directors, partners, employees, agents, licensors, and suppliers, harmless from and against any claims, actions or demands, liabilities and settlements including without limitation, reasonable legal and accounting fees, resulting from, or alleged to result from, your violation of this Terms of Use Agreement.

PROGENICS SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THIS WEB SITE, EVEN IF Progenics HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INCLUDING BUT NOT LIMITED TO RELIANCE BY ANY PARTY ON ANY CONTENT OBTAINED THROUGH THE USE OF THIS WEB SITE, OR THAT ARISES IN CONNECTION WITH MISTAKES OR OMISSIONS IN, OR DELAYS IN TRANSMISSION OF, INFORMATION TO OR FROM THE USER, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THIS WEB SITE OR VIRUSES, WHETHER CAUSED IN WHOLE OR IN PART BY NEGLIGENCE, ACTS OF GOD, TELECOMMUNICATIONS FAILURE, THEFT OR DESTRUCTION OF, OR UNAUTHORIZED ACCESS TO THIS WEB SITE, OR RELATED INFORMATION OR PROGRAMS. Because some countries and states do not allow the exclusion or limitation of liability for consequential or incidental damages, all disclaimers, limitations and other terms of this paragraph shall apply to the greatest extent permitted by law.

This Website and its content are intended to comply with the laws and regulations in the U.S.  Although the information on this Website is accessible to users outside of the U.S., the information pertaining to Progenics’ products is intended for use only by residents of the U.S. Other countries may have laws, regulatory requirements and medical practices that differ from those in the U.S. This Website links to other sites produced by Progenics’ various operating divisions and subsidiaries, some of which are outside the U.S. Those sites may have information that is appropriate only to that particular originating country. Progenics reserves the right to limit provision of its products or services to any person, geographic region or jurisdiction and/or to limit the quantities or any products or services it provides. Any offer for any product or service made on this Website is void where prohibited.

This Terms of Use Agreement and your use of the Website shall be governed by the laws of the United States of America and the State of New York without regard to its conflicts of laws principles. Any legal action or proceeding related to this Website shall be brought exclusively in a federal or state court of competent jurisdiction sitting in New York.

Progenics reserves the right to alter or delete materials from this Website at any time at its discretion.

Approved Use:

AZEDRA® (iobenguane I 131) is a prescription medicine used to treat adult and pediatric patients 12 years and older with cancers known as pheochromocytoma and paraganglioma that are positive for the norepinephrine transporter (as determined by an iobenguane scan), and who require systemic anticancer therapy.

Important Safety Information

AZEDRA can cause serious side effects. If you experience these side effects, your health care provider may need to adjust or stop your treatment. You should always follow your health care provider’s instructions. Serious side effects may include:

  • Radiation exposure: Treatment with AZEDRA will expose you to radiation which can contribute to your overall long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. Radiation risk is greater in children than in adults. You should stay well hydrated before, during, and after your treatment and urinate frequently. Your doctor will advise you on how to lessen exposure to people who may come into contact with you after AZEDRA treatment.
  • Bone marrow problems and other cancers: Treatment with AZEDRA may cause your blood cell counts to drop (myelosuppression). You may experience blood-related side effects such as low numbers of cells that are responsible for blood clotting (thrombocytopenia), low numbers of a type of white blood cells (neutropenia), and low red blood cells (anemia). Among the 88 patients who received a therapeutic dose of AZEDRA, 33% experienced Grade 4 thrombocytopenia, 16% experienced Grade 4 neutropenia, and 7% experienced Grade 4 anemia. Five percent of patients experienced febrile neutropenia (neutropenia with fever). People with low blood counts can develop serious infections. Your health care provider will routinely check your blood counts and tell you if they are too low. Tell your doctor if you experience any symptoms of low blood counts or infection, such as fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly. Other conditions that you may develop as a direct result of treatment with AZEDRA are blood and bone marrow cancers known as secondary myelodysplastic syndrome (MDS) and leukemia. MDS or acute leukemias were reported in 6.8% of the 88 patients who received a therapeutic dose of AZEDRA. The time to development of MDS or acute leukemia ranged from 12 months to 7 years. Two of the 88 patients developed other types of cancer.
  • Thyroid problems: Treatment with AZEDRA may increase your long-term risk of developing an underactive thyroid (hypothyroidism) or thyroid cancer. Hypothyroidism was reported in 3.4% of the 88 patients who received a therapeutic dose of AZEDRA. Take all thyroid-blocking agents as prescribed by your doctor to reduce the risk of these problems. You may need life-long monitoring for signs and symptoms of hypothyroidism.
  • Elevations in blood pressure: During or 24 hours following AZEDRA treatment, you may experience increases of blood pressure (hypertension) as a result of hormones released from your cancer. Eleven percent of the 88 patients who received a therapeutic dose of AZEDRA experienced a worsening of pre-existing hypertension. All changes in blood pressure occurred within the first 24 hours after treatment. Monitor blood pressure frequently during the first 24 hours after each therapeutic dose of AZEDRA. Tell your doctor if you experience any cardiac-related symptoms.
  • Kidney problems: Treatment with AZEDRA will expose your kidneys to radiation and may impair their ability to work as normal. In some cases, patients have experienced kidney failure after treatment with AZEDRA. Of the 88 patients who received a therapeutic dose of AZEDRA, 9% developed kidney failure or acute kidney injury, and 22% experienced a decrease in kidney function measured at 6 or 12 months. Your health care provider will monitor your kidneys after treatment using blood tests, particularly if you already have kidney impairment before treatment.
  • Respiratory problems: Treatment with AZEDRA may cause noninfectious lung inflammation (pneumonitis). Tell your doctor if you experience shortness of breath, difficulty breathing, or cough.
  • Pregnancy warning: Before treatment with AZEDRA, tell your doctor if you are pregnant or plan to become pregnant. Exposure to radiation from treatment with AZEDRA can harm your unborn baby. Use an effective method of birth control during treatment with AZEDRA and for 7 months (for females) and 4 months (for males) after your final dose. Do not breastfeed during treatment with AZEDRA and for 80 days after your final dose.
  • Fertility problems: Treatment with AZEDRA may cause infertility due to radiation absorbed by your testes or ovaries over the treatment period that is within the range of exposure where temporary or permanent infertility may be expected.
    The most common and most serious side effects of AZEDRA include decreased blood cell counts, nausea, vomiting and fatigue. These are not all the possible side effects of AZEDRA. For more information, ask your health care provider.
    Drugs that reduce catecholamine uptake or that deplete catecholamine stores may interact with AZEDRA and may affect how well it works. These drugs were not permitted in the clinical trials. Tell your doctor before starting any medication, including over the counter medications, herbal or dietary supplements.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for AZEDRA.

Distributed by: Progenics Pharmaceuticals, Inc., NY 10007

Reference: AZEDRA® prescribing information. New York, NY: Progenics Pharmaceuticals, Inc.; 07 2018.